Login or sign up
For business
Average ratingGreat
4.3/ 5

Based on 8 reviews

550%
425%
325%
20%
10%
Ask AI

Questions about Stimunity

Based on 8 reviews, listing data and website checks · updated 6 days ago

What is Stimunity?

Stimunity is a preclinical-stage biopharmaceutical startup developing drugs on the STING pathway to treat patients unresponsive to conventional immunotherapy. The company aims to activate the innate immune system to fight infectious pathogens or cancer. Their technology is based on high-level academic research from Institut Curie, Inserm, and the University of Oxford.

What specific scientific discoveries form the basis of Stimunity's technology?

The company's core technology relies on STING-activating Virus-Like Particles discovered by Dr. Nicolas Manel's lab at Institut Curie. This 'Trojan horse' mechanism was published in Science in 2015 and is central to their drug development strategy. The team also has prior research on the cGAS-STING pathway in HIV immune recognition published in Immunity in 2013.

Where is Stimunity based and what industry does it operate in?

Stimunity is located in Paris, Île-de-France, with its headquarters at 57, rue d'Amsterdam, 75008 Paris — France. The company operates within the biotechnology industry and focuses on biopharmaceuticals for patients who do not respond to standard treatments. It is a French entity registered as Stimunity SAS.

Who are the key founders and what is their professional background?

The company was founded by Sylvain Carlioz, who previously worked as a Business Development & Licensing Manager at the Institut Curie technology transfer office. He also spent time in the Novartis Venture Fund's team through the European Entente Health Program. Scientific Advisor Dr. Nicolas Manel is a Director of Research at INSERM and Group Leader at Institut Curie.

What funding has Stimunity secured to advance its research?

Stimunity received a seed investment of 2M€ from Portage Biotech, a public listed venture company trading on NASDAQ under the ticker PRTG. The company also secured funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 888939. These investments support their move through clinical trials.

What is the current rating and review history on Trustburn?

The Trustburn listing shows a rating of 4.3 out of 5 stars from 8 reviews. The most recent review was posted on October 26, 2023, while the oldest review in the set dates back to December 14, 2022. The reviews are overwhelmingly positive, with several 5-star ratings highlighting product quality and customer service.

What aspects of the customer experience do reviewers highlight?

Reviewers consistently praise Stimunity's outstanding customer service and the user-friendliness of their website. Many users found the site easy to navigate and informative, containing all necessary information. The high quality of products and prompt service were also frequently mentioned in the feedback.

How is the company structured and who leads it?

The company's management team includes Sylvain Carlioz as CEO & Founder and Dr. Nicolas Manel as Scientific Advisor & Founder. The team leverages expertise from prestigious institutions like Institut Curie, Inserm, and the University of Oxford to develop their drugs. This academic background is a key feature of their operational structure.

What specific products or services does Stimunity offer?

Stimunity develops best-in-class drugs specifically targeting the STING pathway to activate the innate immune system. Their products are designed to stimulate the immune system to fight back against infectious pathogens or cancer. This approach is intended for patients that do not respond to conventional immunotherapy.

What stage of development is Stimunity in and who is its target audience?

Stimunity operates in the biotechnology sector, specifically focusing on biopharmaceuticals. The company is a preclinical-stage startup that aims to move its assets through clinical trials. Their target market includes patients who have failed to respond to standard immunotherapy treatments.

How do users describe the Stimunity website?

The company's website is described by reviewers as user-friendly, intuitive, and well-designed. It provides all the necessary information and is easy to navigate. The site's design and content are considered top-notch and informative by users.

What qualities do reviewers attribute to the Stimunity team?

Stimunity's staff is frequently praised for being helpful, informative, friendly, and knowledgeable. The service is described as prompt, professional, and top-notch. Customers appreciate the attention to detail and the ability to meet their needs.

Which academic institutions support Stimunity's research?

The company has received significant academic backing from Institut Curie, Inserm, and the University of Oxford. These institutions provided the high-level research work that forms the basis of their technology. The collaboration between academia and industry is a defining characteristic of their approach.

How can I contact Stimunity?

You can reach Stimunity by e-mail at contact@stimunity.com.

Is Stimunity on social media?

Stimunity has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Stimunity

Biopharmaceuticals to treat patients that do not respond to conventional immunotherapy.

Categories
Biotechnology